Diagnostic Approach and Management of Hyperostosis Frontalis Interna

Diagnostic Evaluation

The National Kidney Foundation recommends measuring serum calcium, phosphorus, creatinine, alkaline phosphatase (ALP), parathyroid hormone (PTH), and 25(OH) vitamin D levels to differentiate HFI from treatable metabolic conditions 1
MRI of the skull with black bone sequence is the preferred imaging modality for accurate bone structure evaluation, as conventional skull radiography has no place in modern metabolic bone disease diagnosis 1
The American Academy of Neurology recommends topiramate as first-line prophylaxis for headache management in HFI patients, starting with 25mg and increasing weekly to 50mg twice daily 3

Paget's disease presents with mixed osteolytic/osteosclerotic skull lesions, elevated ALP, age >50 years, and characteristic deformities, requiring treatment unlike HFI 1, 2
Hyperparathyroidism causes elevated ALP and PTH with metabolic derangements requiring specific intervention 2
Osteomalacia shows generalized bone pain, muscle weakness, low phosphorus, elevated ALP, low vitamin D, and elevated PTH, all of which are treatable conditions 1, 2
Hypophosphatasia presents with bone pain and muscle weakness but with low ALP levels, opposite of other metabolic bone diseases 1, 2

OnabotulinumtoxinA (Botox) is FDA-approved specifically for chronic migraine prophylaxis in HFI patients 3
Cognitive-behavioral therapy, relaxation training, and biofeedback are effective non-pharmacological interventions for headache management in HFI patients 3
Giant cell arteritis should be considered in patients with scalp tenderness, jaw claudication, or temporal pain, and requires immediate ESR, CRP, and temporal artery biopsy evaluation 4
Drug-induced hyperostosis may occur in patients with a history of isotretinoin or acitretin use, though this typically affects the spine rather than skull 5